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Alzheimer’s disease is the most common type of
dementia, and it is characterized by a decline in
memory or other thinking skills. The greatest risk
factor for Alzheimer’s disease is advanced age. A
recent genome-wide study identified a locus on
chromosome 17 associated with the age at onset, and
a specific variant in CCL11 is probably responsible for
the association. The association of a protective
haplotype with a 10-year delay in the onset of
Alzheimer’s disease and the identification of a CCL11
variant with possible functional roles in this
association might allow the future development of
immunomodulators with the potential to halve
disease incidence.considered together [6].Alzheimer’s disease (AD) is a common and multifactorial
neurodegenerative disease. It is one of the leading causes
of death around the world and is associated with sub-
stantial direct and indirect costs for families and soci-
eties. The vast majority of AD cases have a late onset
(usually after 65 years of age); the disease is rare among
younger individuals. Incidence of AD is known to in-
crease with age, and age is the most important risk
factor for the development of AD. The ability to delay
the age at onset (AAO) of this disease through prevent-
ive or therapeutic approaches would have significant
benefits, but no therapies have been successful in achiev-
ing this important goal [1, 2]. A recent study by Lalli et al.
[3] used genome-wide technologies to identify genetic
modifiers of AAO in a unique cohort comprising an
extended Colombian family carrying the PSEN1 p.E280A
mutation, and the outcome might be useful for guiding
the search for therapies.
Age at onset as a highly heritable factor in AD
AAO is highly heritable in AD families. In early-onset
cases, mutations in three genes are known to account* Correspondence: r.guerreiro@ucl.ac.uk
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Protein (APP), Presenilin-1 (PSEN1) and Presenilin-2
(PSEN2). However, the genes involved in AAO variance
mostly remain to be identified; linkage and candidate
gene studies have established several possible associations
with different loci, but the only consistently replicated
modulator of AD AAO, in both familial and sporadic
cases, is also the strongest genetic risk locus for the devel-
opment of the disease (APOE) [5]. More recently, Naj et
al. [6] performed a large genome-wide association study
(GWAS) in over 9000 patients to detect effects of known
AD risk loci in modifying AAO. They confirmed the asso-
ciation of APOE Ɛ4 allele with earlier onset and identified
associations with CR1, BIN1 and PICALM. Burden ana-
lyses showed that APOE contributed 3.7 % of AAO vari-
ation; the other nine loci studied contributed 2.2 % when
Many of these studies suffered from confounders, such
as genetic and phenotypic heterogeneity, population
stratification or inaccurate phenotyping. In fact, AAO of
a disease is often a very difficult parameter to record
with precision when assessed retrospectively. Lalli et al.
[3] reduced the effects of many of these confounders by
assessing a unique cohort of 72 Colombian patients car-
rying the same PSEN1 mutation (p.E280A) who are part
of an extended family and who have been subjected to
careful prospective phenotyping. By analyzing the gen-
ome sequence of individuals with different AAOs, the
authors [3] identified a locus on chromosome 17q12 that
showed a significant association with AAO in this cohort.
Within this associated locus, they were able to identify a
rare variant (p.A23T) in CCL11 (which encodes the che-
mokine eotaxin-1) associated with a 10-year delay in AAO
of AD [3].Age and immune response in AD
What seemed like a farfetched idea a few years ago is
now a well established fact in AD: inflammatory and im-
mune responses have a significant role in its development
and progression. Several of the genetic loci associated with
AD risk contain genes with known roles in inflammation,
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EPHA1, HLA-DRB5, HLA-DRB1, INPP5D, MEF2C and
TREM2). Pathway analyses of GWAS data have identified
the immune response as important in AD, and an in-
tegrated network analysis of genome and transcriptome
data identified the immune and microglia module as sig-
nificant for AD and TYROBP as the driver gene for this
module [7, 8].
Microglial activation and monocyte/macrophage-me-
diated inflammatory responses are currently particularly
interesting areas of research on AD. To evaluate the re-
lationship between known AD risk loci, Chan et al. [9]
recently conducted a protein quantitative trait analysis
in monocytes and showed that the NME8 risk allele in-
fluences protein tyrosine kinase 2 β (PTK2B), the CD33
risk allele influences triggering receptor expressed on
myeloid cells 2 (TREM2) and the TREM1 risk allele is
associated with a decreased TREM1/TREM2 ratio. Inter-
estingly, the authors [9] also uncovered potential differ-
ences associated with age in the expression of genes in the
TREM locus. TREM1 expression was found to increase
with advancing age in younger but not in older individ-
uals, and TREM1 variants were found to affect TREM2
expression in younger but not older people [9].
AAO as a therapeutic target
The ability to delay the AAO of AD through preventive
or therapeutic approaches would have significant bene-
fits. A 2012 study found a protective variant in APP,
which suggests that manipulating the amyloid pathway
could be a successful approach to reducing AD [10].
One can predict that other elements participating dir-
ectly or indirectly in the proteolytic processing of
APP will also be good therapeutic targets to modulate
the disease.
Similarly, the variant found in CCL11 in the most
recent study by Lalli et al. [3] also has a high potential
as a therapeutic target. It encodes eotaxin, and the con-
centration of eotaxin has been shown previously to rise
with age both in people and in mice. Eotaxin has also
been identified as potentially one of the most deleterious
factors for cognitive function and neurogenesis in aging
by parabiosis studies in which the blood of two mice,
one young and one old, was shared through the surgical
fusion of vascular systems [11]. The variant identified by
Lalli et al. [3] (p.A23T) is located in the protein signal
peptide cleavage site, suggesting a functional role for the
variant, possibly through the binding with its receptor
(CCR3). The enhanced secretion of eotaxin by cells
transfected with this variant [3] validate the functional
significance of the variant, but, given the protective role
of lower levels of eotaxin, the finding of increased cell
secretion is in the opposite direction to what was expec-
ted. These findings clearly demonstrate the need to betterunderstand the biology of genomes and emphasize the
need to further characterize the molecular biology of these
genomic regions.
Concluding remarks
It is important to understand how the recent findings
from isolated and endogamous cohorts will translate to
other populations, and what the implications are for the
understanding of late-onset AD. Although single rare
variants will not have high population-attributable risks,
they will be extremely important for individual risk pre-
diction and for the understanding of biology and patho-
biology. Likewise it will be important to understand how
findings made in early-onset familial cases will translate
to the most common and sporadic late-onset AD. Two
observations support significant commonalities between
these two forms of disease, suggesting that factors im-
portant for early-onset and familial cases will also be im-
portant for late-onset and sporadic AD: first, the APOE
Ɛ4 allele not only modulates the AAO of AD in a spor-
adic setting, but also in carriers of presenilin mutations,
and second, the identification of the protective effect of
APP p.A673T in the Icelandic population showed that
amyloid β has crucial roles in both early- and late-onset
AD [10].
The mechanisms through which eotaxin and other
peripheral immune molecules contribute to the disease
process are still to be determined, but the identification
of an association between CCL11 and AAO in the studied
Colombian kindred [3], if validated, can potentially be
translated into immunomodulating therapies able to delay
the onset of AD in the future.
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